EUCTR2006-004997-28-IT进行中（未招募）不适用
Studio Multicentrico, di Fase III, randomizzato, in doppio cieco, controllato verso trattamento attivo e verso placebo, con sospensione randomizzata del farmaco in studio, per valutare la sicurezza e l'efficacia di CG5503 RP orale in pazienti con dolore cronico da cancro di intensita' moderata-severa. - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 573
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the trial and are willing to participate in the trial. Male and non-pregnant, non-lactating female subjects. Sexually active women must be post menopausal, surgically sterile, or practicing an effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization) before entry and throughout the trial. Female subjects must have a negative pregnancy test at Screening. At least 18 years of age. Chronic malignant tumor-related pain. Subjects who are opioid-naive or pretreated with an equianalgesic dose range equivalent of up to 160 mg oral morphine per day and are dissatisfied with prior treatment. Subjects with a mean pain intensity >= 5 points (11-point NRS) on the day of randomization at the start of Titration phase. Expected course of the disease and the pain that will permit compliance with the trial protocol over the entire trial period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •General: History of alcohol and/or drug abuse in the investigator's judgment, based on patient history and physical examination. The subject has a clinically significant disease other than cancer which in the investigator's opinion may affect efficacy or safety assessments eg, significant unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric (resulting in disorientation, memory impairment or inability to report accurately) or metabolic disturbances. Any scheduled surgery during the trial. Any painful procedure during the trial that may, in the opinion of the Investigator, affect the efficacy or safety assessments. Employees of the investigator or trial center, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial center, as well as family members of the employees or the investigator. Known to or suspected of not being able to comply with the protocol and the use of CG5503 or morphine. Have received an experimental drug or used an experimental medical device within 30 days before the planned start of treatment. Participation in another trial concurrently. Subjects who have participated in previous trials of CG5503. Trial Specific: Life-long history of seizure disorder or epilepsy, or any of the following within one year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or severe traumatic brain injury within 15 years (consisting of >= 1 of the following: brain contusion, intracranial hematoma, either unconsciousness or post-traumatic amnesia lasting for more than 24 hours) or with residual sequelae suggesting transient changes in consciousness. Known history and/or presence of cerebral metastases. Subjects with moderately or severely impaired hepatic function, or subjects with laboratory values reflecting inadequate hepatic function (ALT, AST greater than three-fold upper limit of normal). Inadequate baseline bone marrow reserve with WBC count <= 3 500/ L, platelet count <= 100 000/ L, and hemoglobin level <= 9.5 mg/dL. Subjects with severely impaired renal function. Subjects with hypercalcemia, ie, corrected total serum calcium levels higher than 3.0 mmol/L. Subjects taking any prohibited concomitant medications (as specified below) Uncontrolled hypertension (repeated measurements of systolic blood pressure > 160 mmHg or diastolic blood pressure > 95 mmHg). Clinically relevant history of hypersensitivity, allergy or contraindications to morphine or any of the excipients. Chronic hepatitis B or C, or HIV, or presence of active hepatitis B or C within the past 3 months
研究者
相似试验
进行中（未招募）
不适用
Estudio fase III, multicéntrico, randomizado, abierto, para comparar la eficacia y seguridad de un régimen de tratamiento basado en Sitagliptina frente a un régimen de tratamiento basado en Liraglutida en pacientes con Diabetes Mellitus Tipo 2 en monoterapia con Metformina que no han alcanzado un adecuado control glucémico.A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy.Diabetes Mellitus tipo 2Type 2 diabetes mellitusMedDRA version: 13Level: PTClassification code 10067585Term: Diabetes mellitus tipo 2EUCTR2010-023759-27-ESMerck Sharp & Dohme Corp600
进行中（未招募）
不适用
Etude de phase III randomnisée, multicentrique comparant une chimiothérapie d’induction par TPF suivie d’une association radiothérapie Erbitux® versus une radiochimiothérapie concomitante chez des patients présentant un carcinome épidermoïde des VADS localement évolué inopérable - Radiochimiothérapie HNSCC, essai Randomnisé, Taxotère cisplatine, 5FU, ErbituxEUCTR2008-005760-14-BEGORTEC324
进行中（未招募）
1 期
Estudio fase III, multicéntrico, randomizado, doble ciego, controlado con placebo, de eficacia y seguridad de Apremilast (CC-10004) en pacientes con psoriasis en placas moderada o severa. A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasisPsoriasis, una enfermedad crónica inflamatoria de la piel, se calcula que afecta hasta el 2,5% de la población mundial. La psoriasis en placas es la forma más común de esta enfermedad.?Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world'spopulation. Plaque-type psoriasis is the most common form of this disease.MedDRA version: 12.1Level: LLTClassification code 10037153Term: PsoriasisEUCTR2010-019992-30-ESCelgene Corporation405
进行中（未招募）
不适用
Estudio fase III, multicéntrico, randomizado, controlado, doble ciego, con grupos de tratamiento paralelos, para evaluar la seguridad y eficacia de Rituximab en combinación con metotrexato (MTX), en comparación con metotrexato sólo en pacientes con artritis reumatoide activa no tratados previamente con metotrexato”EUCTR2005-002395-15-ESF. Hoffmann-La Roche Ltd.853
进行中（未招募）
1 期
Etude de phase III randomisée, multicentrique comparant une chimiothérapie d’induction par TPF suivie d’une association radiothérapie Erbitux® versus une radiochimiothérapie concomitante chez des patients présentant un carcinome épidermoïde des VADS localement évolué inopérable - Radiochimiothérapie HNSCC, Esssai randomisé, Taxotère, cisplatine5 FU, ErbituxCet essai sera proposé aux patients porteurs de carcinome épidermoïde histologiquement prouvé de la cavité buccale, de l'oropharynx, du larynx, ou de l'hypopharynx, de stadeIV non métastatique (carcinome localement évolué inopérable).MedDRA version: 9.1 Level: LLT Classification code 10060121 Term: Squamous cell carcinoma of head and neckEUCTR2008-005760-14-FRGORTEC314